Five months after the CEO of Mylan faced an irate House panel over price increases for its EpiPen auto injectors, a former competitor will be back next month — at a far higher list price, the company announced.
Government Solution Not Needed to Reduce Drug Costs
In a recent article in the Bristol Herald Courier, David Balto gives a great summary of the problems with the pharmacy benefit management industry, such